

**TDMS No.** 99017 - 06

**Test Type:** CHRONIC

**Route:** RESPIRATORY EXPOSURE WHOLE BODY

**Species/Strain:** MICE/B6C3F1

**P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS**

Diethylamine

**CAS Number:** 109-89-7

F1\_M3

**Date Report Requested:** 10/23/2008

**Time Report Requested:** 13:20:12

**First Dose M/F:** 08/18/03 / 08/18/03

**Lab:** BNW

**C Number:** C99017  
**Lock Date:** 08/01/2006  
**Cage Range:** ALL  
**Date Range:** ALL  
**Reasons For Removal:** ALL  
**Removal Date Range:** ALL  
**Treatment Groups:** Include ALL  
**Study Gender:** Both  
**TDMSE Version:** 2.0.0

TDMS No. 99017 - 06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS

Diethylamine

CAS Number: 109-89-7

Date Report Requested: 10/23/2008

Time Report Requested: 13:20:12

First Dose M/F: 08/18/03 / 08/18/03

Lab: BNW

## HISTORICAL CONTROL STUDIES From October 2007 Report

### SAME ROUTE

- 96011-06 -- Cumene (INHALATION AIR)
- 88004-06 -- Divinylbenzene (INHALATION AIR)
- 97006-02 -- Methyl isobutyl ketone (INHALATION AIR)
- 88006-04 -- alpha-Methylstyrene (INHALATION AIR)
- 97008-06 -- Propargyl alcohol (INHALATION AIR)
- 96001-06 -- Stoddard solvent (type IIC) (INHALATION AIR)

### ALL ROUTES

- 88138-04 -- Benzophenone (ORAL FEED)
- 99027-04 -- Chromium picolinate monohydrate (ORAL FEED)
- 05174-06 -- Cresols (ORAL FEED)
- 96011-06 -- Cumene (INHALATION AIR)
- 97003-08 -- 1,2-Dibromo-2,4-dicyanobutane (SKIN ETHANOL)
- 93020-08 -- Diisopropylcarbodiimide (SKIN ETHANOL)
- 88004-06 -- Divinylbenzene (INHALATION AIR)
- 88123-07 -- Formamide (GAVAGE WATER)
- 95011-06 -- 5-(Hydroxymethyl)-2-furfural (GAVAGE WATER)
- 88105-04 -- Isoeugenol (GAVAGE CORN OIL)
- 97006-02 -- Methyl isobutyl ketone (INHALATION AIR)
- 91005-08 -- Methylene blue trihydrate (GAVAGE METHYLCELLULOSE)
- 92013-06 -- 4-Methylimidazole (ORAL FEED)
- 88006-04 -- alpha-Methylstyrene (INHALATION AIR)
- 99023-04 -- beta-Myrcene (GAVAGE CORN OIL)
- 97008-06 -- Propargyl alcohol (INHALATION AIR)
- 20114-06 -- Sodium dichromate dihydrate (VI) (ORAL WATER)
- 96001-06 -- Stoddard solvent (type IIC) (INHALATION AIR)
- 05109-14 -- Triethanolamine (SKIN ACETONE)

**TDMS No.** 99017 - 06

**Test Type:** CHRONIC

**Route:** RESPIRATORY EXPOSURE WHOLE BODY

**Species/Strain:** MICE/B6C3F1

**P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS**

Diethylamine

**CAS Number:** 109-89-7

**Date Report Requested:** 10/23/2008

**Time Report Requested:** 13:20:12

**First Dose M/F:** 08/18/03 / 08/18/03

**Lab:** BNW

**HISTORICAL CONTROL STUDIES  
From October 2007 Report**

- 96019-06 -- Water disinfection byproducts (Bromochloroacetic acid) (ORAL WATER)
- 96018-04 -- Water disinfection byproducts (Bromodichloromethane) (ORAL WATER)
- 96017-06 -- Water disinfection byproducts (Dibromoacetic acid) (ORAL WATER)
- 96015-06 -- Water disinfection byproducts (Dibromoacetonitrile) (ORAL WATER)
- 96010-04 -- Water disinfection byproducts (Sodium chlorate) (ORAL WATER)

**TDMS No.** 99017 - 06

**Test Type:** CHRONIC

**Route:** RESPIRATORY EXPOSURE WHOLE BODY

**Species/Strain:** MICE/B6C3F1

**P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS**

Diethylamine

**CAS Number:** 109-89-7

**Date Report Requested:** 10/23/2008

**Time Report Requested:** 13:20:12

**First Dose M/F:** 08/18/03 / 08/18/03

**Lab:** BNW

**FOR ALL DOSES THE TUMOR RATES IN THE FOLLOWING TISSUES/ORGANS ARE BASED ON NUMBER OF TISSUES EXAMINED.  
IN OTHER TISSUES/ORGANS RATES ARE BASED ON THE NUMBER OF ANIMALS NECROPSIED.**

Adrenal Cortex  
Adrenal Medulla  
Bone Marrow  
Brain  
Epididymis  
Gallbladder  
Heart  
Islets, Pancreatic  
Kidney  
Liver  
Lung  
Ovary  
Pancreas  
Pituitary Gland  
Salivary Glands  
Spleen  
Thyroid Gland  
Urinary Bladder

TDMS No. 99017 - 06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

**P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS**

Diethylamine

CAS Number: 109-89-7

Date Report Requested: 10/23/2008

Time Report Requested: 13:20:12

First Dose M/F: 08/18/03 / 08/18/03

Lab: BNW

**SUMMARY OF STATISTICALLY SIGNIFICANT ( $P \leq .05$ ) RESULTS IN THE ANALYSIS OF Diethylamine**

**MALE MICE**

**Organ**

Harderian Gland  
Stomach, Forestomach

**Morphology**

Carcinoma or Adenoma  
Squamous Cell Carcinoma

**FEMALE MICE**

**Organ**

Harderian Gland

Liver

Mammary Gland

Ovary

Spleen

All Organs

**Morphology**

Adenoma  
Carcinoma or Adenoma  
Hepatocellular Carcinoma or Hepatocellular Adenoma  
Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma  
Carcinoma  
Fibroma, Fibroadenoma, Carcinoma, or Adenoma  
Cystadenoma  
Hemangiosarcoma  
Hemangiosarcoma  
Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed, NOS, or  
Undifferentiated Cell Type

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Adrenal Cortex  
Adenoma**

**TUMOR RATES**

OVERALL (a)	6/50 (12%)	4/50 (8%)	6/50 (12%)	2/50 (4%)
POLY-3 RATE (b)	6/43.3	4/46.17	6/43.61	2/45.33
POLY-3 PERCENT (g)	13.9%	8.7%	13.8%	4.4%
TERMINAL (d)	5/31 (16%)	3/38 (8%)	5/32 (16%)	2/37 (5%)
FIRST INCIDENCE	606	610	610	729 (T)
HC TUMORS SAME RTE	11/297 (4%)			
HC TUMORS ALL RTES	74/1092 (7%)			

**STATISTICAL TESTS**

POLY 3	P=0.127N	P=0.329N	P=0.617N	P=0.118N
POLY 1.5	P=0.132N	P=0.347N	P=0.619N	P=0.125N
POLY 6	P=0.121N	P=0.305N	P=0.610N	P=0.108N
COCH-ARM / FISHERS	P=0.137N	P=0.370N	P=0.620N	P=0.134N
MAX-ISO-POLY-3	P=0.118N	P=0.226N	P=0.494N	P=0.063N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Adrenal Medulla  
Pheochromocytoma: Benign, Complex, Malignant, NOS**

**TUMOR RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/42.87	0/45.75	0/43.2	1/45.33
POLY-3 PERCENT (g)	0%	0%	0%	2.2%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	1/37 (3%)
FIRST INCIDENCE	---	---	---	729 (T)
HC TUMORS SAME RTE	3/294 (1%)			
HC TUMORS ALL RTES	8/1085 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.204	(e)	(e)	P=0.511
POLY 1.5	P=0.202	(e)	(e)	P=0.506
POLY 6	P=0.207	(e)	(e)	P=0.518
COCH-ARM / FISHERS	P=0.200	(e)	(e)	P=0.500
MAX-ISO-POLY-3	P=0.143	(e)	(e)	P=0.172
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Bone Marrow  
Hemangiosarcoma**

**TUMOR RATES**

OVERALL (a)	2/50 (4%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/43.22	2/45.8	0/43.2	0/45.33
POLY-3 PERCENT (g)	4.6%	4.4%	0%	0%
TERMINAL (d)	1/31 (3%)	1/38 (3%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	632	718	---	---
HC TUMORS SAME RTE	2/299 (1%)			
HC TUMORS ALL RTES	7/1092 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.086N	P=0.673N	P=0.237N	P=0.227N
POLY 1.5	P=0.087N	P=0.682N	P=0.238N	P=0.231N
POLY 6	P=0.084N	P=0.660N	P=0.236N	P=0.220N
COCH-ARM / FISHERS	P=0.088N	P=0.691N	P=0.247N	P=0.247N
MAX-ISO-POLY-3	P=0.120N	P=0.476N	P=0.076N	P=0.076N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

---



**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>Harderian Gland Adenoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	4/50 (8%)	6/50 (12%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	4/42.87	6/46.34	2/43.29	1/45.38
POLY-3 PERCENT (g)	9.3%	13%	4.6%	2.2%
TERMINAL (d)	4/31 (13%)	5/38 (13%)	1/32 (3%)	0/37 (0%)
FIRST INCIDENCE	729 (T)	541	705	715
HC TUMORS SAME RTE	38/300 (13%)			
HC TUMORS ALL RTES	143/1099 (13%)			

**STATISTICAL TESTS**

POLY 3	P=0.059N	P=0.419	P=0.332N	P=0.161N
POLY 1.5	P=0.063N	P=0.397	P=0.335N	P=0.169N
POLY 6	P=0.054N	P=0.450	P=0.325N	P=0.150N
COCH-ARM / FISHERS	P=0.068N	P=0.370	P=0.339N	P=0.181N
MAX-ISO-POLY-3	P=0.089N	P=0.302	P=0.197N	P=0.079N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>Harderian Gland Carcinoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	4/50 (8%)	7/50 (14%)	1/50 (2%)	3/50 (6%)
POLY-3 RATE (b)	4/42.87	7/45.75	1/43.2	3/45.33
POLY-3 PERCENT (g)	9.3%	15.3%	2.3%	6.6%
TERMINAL (d)	4/31 (13%)	7/38 (18%)	1/32 (3%)	3/37 (8%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	729 (T)
HC TUMORS SAME RTE	11/300 (4%)			
HC TUMORS ALL RTES	29/1099 (3%)			

**STATISTICAL TESTS**

POLY 3	P=0.206N	P=0.299	P=0.176N	P=0.470N
POLY 1.5	P=0.215N	P=0.282	P=0.178N	P=0.484N
POLY 6	P=0.193N	P=0.324	P=0.172N	P=0.449N
COCH-ARM / FISHERS	P=0.227N	P=0.262	P=0.181N	P=0.500N
MAX-ISO-POLY-3	P=0.153N	P=0.206	P=0.082N	P=0.324N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>Harderian Gland Carcinoma or Adenoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	8/50 (16%)	13/50 (26%)	3/50 (6%)	4/50 (8%)
POLY-3 RATE (b)	8/42.87	13/46.34	3/43.29	4/45.38
POLY-3 PERCENT (g)	18.7%	28.1%	6.9%	8.8%
TERMINAL (d)	8/31 (26%)	12/38 (32%)	2/32 (6%)	3/37 (8%)
FIRST INCIDENCE	729 (T)	541	705	715
HC TUMORS SAME RTE	48/300 (16%)			
HC TUMORS ALL RTES	166/1099 (15%)			

**STATISTICAL TESTS**

POLY 3	P=0.027N*	P=0.212	P=0.093N	P=0.149N
POLY 1.5	P=0.031N*	P=0.189	P=0.097N	P=0.162N
POLY 6	P=0.023N*	P=0.249	P=0.088N	P=0.131N
COCH-ARM / FISHERS	P=0.039N*	P=0.163	P=0.100N	P=0.178N
MAX-ISO-POLY-3	P=0.035N*	P=0.156	P=0.050N*	P=0.094N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Intestine Small: Jejunum  
Carcinoma**

TUMOR RATES	#	#	#	#
OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	2/42.98	0/45.75	0/43.2	1/45.37
POLY-3 PERCENT (g)	4.7%	0%	0%	2.2%
TERMINAL (d)	1/31 (3%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	702	---	---	717
HC TUMORS SAME RTE	5/300 (2%)			
HC TUMORS ALL RTES	13/1099 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.473N	P=0.223N	P=0.236N	P=0.481N
POLY 1.5	P=0.468N	P=0.230N	P=0.237N	P=0.490N
POLY 6	P=0.480N	P=0.215N	P=0.234N	P=0.469N
COCH-ARM / FISHERS	P=0.461N	P=0.247N	P=0.247N	P=0.500N
MAX-ISO-POLY-3	P=0.131N	P=0.076N	P=0.076N	P=0.270N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Intestine Small: Site Unspecified  
Carcinoma**

**TUMOR RATES**

	#	#	#	#
OVERALL (a)	2/50 (4%)	1/50 (2%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	2/42.98	1/45.75	0/43.2	1/45.37
POLY-3 PERCENT (g)	4.7%	2.2%	0%	2.2%
TERMINAL (d)	1/31 (3%)	1/38 (3%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	702	729 (T)	---	717
HC TUMORS SAME RTE	5/300 (2%)			
HC TUMORS ALL RTES	17/1099 (2%)			

**STATISTICAL TESTS**

POLY 3	P=0.372N	P=0.478N	P=0.236N	P=0.481N
POLY 1.5	P=0.371N	P=0.488N	P=0.237N	P=0.490N
POLY 6	P=0.373N	P=0.465N	P=0.234N	P=0.469N
COCH-ARM / FISHERS	P=0.369N	P=0.500N	P=0.247N	P=0.500N
MAX-ISO-POLY-3	P=0.225N	P=0.268N	P=0.076N	P=0.270N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Islets, Pancreatic  
Adenoma**

**TUMOR RATES**

OVERALL (a)	2/50 (4%)	1/50 (2%)	0/49 (0%)	1/50 (2%)
POLY-3 RATE (b)	2/43.36	1/45.75	0/42.77	1/45.33
POLY-3 PERCENT (g)	4.6%	2.2%	0%	2.2%
TERMINAL (d)	1/31 (3%)	1/38 (3%)	0/32 (0%)	1/37 (3%)
FIRST INCIDENCE	584	729 (T)	---	729 (T)
HC TUMORS SAME RTE	3/295 (1%)			
HC TUMORS ALL RTES	11/1086 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.372N	P=0.481N	P=0.240N	P=0.485N
POLY 1.5	P=0.372N	P=0.490N	P=0.241N	P=0.492N
POLY 6	P=0.373N	P=0.469N	P=0.238N	P=0.474N
COCH-ARM / FISHERS	P=0.370N	P=0.500N	P=0.253N	P=0.500N
MAX-ISO-POLY-3	P=0.229N	P=0.270N	P=0.078N	P=0.272N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

---

TDMS No. 99017 - 06  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Diethylamine  
 CAS Number: 109-89-7

Date Report Requested: 10/23/2008  
 Time Report Requested: 13:20:12  
 First Dose M/F: 08/18/03 / 08/18/03  
 Lab: BNW

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Islets, Pancreatic  
 Carcinoma or Adenoma**

**TUMOR RATES**

OVERALL (a)	2/50 (4%)	1/50 (2%)	0/49 (0%)	2/50 (4%)
POLY-3 RATE (b)	2/43.36	1/45.75	0/42.77	2/45.33
POLY-3 PERCENT (g)	4.6%	2.2%	0%	4.4%
TERMINAL (d)	1/31 (3%)	1/38 (3%)	0/32 (0%)	2/37 (5%)
FIRST INCIDENCE	584	729 (T)	---	729 (T)
HC TUMORS SAME RTE	4/295 (1%)			
HC TUMORS ALL RTES	12/1086 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.592	P=0.481N	P=0.240N	P=0.678N
POLY 1.5	P=0.590	P=0.490N	P=0.241N	P=0.685N
POLY 6	P=0.594	P=0.469N	P=0.238N	P=0.667N
COCH-ARM / FISHERS	P=0.589	P=0.500N	P=0.253N	P=0.691N
MAX-ISO-POLY-3	P=0.413N	P=0.270N	P=0.078N	P=0.481N
HISTCONT SAME RTE	P=0.190	P=0.479	(e)	P=0.142
HISTCONT ALL RTES	P=0.178	P=0.429	(e)	P=0.120

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Kidney: Renal Tubule  
Carcinoma or Adenoma**

**TUMOR RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	2/49 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	0/45.75	2/42.67	0/45.33
POLY-3 PERCENT (g)	0%	0%	4.7%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	2/32 (6%)	0/37 (0%)
FIRST INCIDENCE	---	---	729 (T)	---
HC TUMORS SAME RTE	1/299 (0%)			
HC TUMORS ALL RTES	14/1094 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.624	(e)	P=0.236	(e)
POLY 1.5	P=0.615	(e)	P=0.234	(e)
POLY 6	P=0.637	(e)	P=0.239	(e)
COCH-ARM / FISHERS	P=0.603	(e)	P=0.242	(e)
MAX-ISO-POLY-3	P=0.262	(e)	P=0.076	(e)
HISTCONT SAME RTE	P=0.315	(e)	P=0.046*	(e)
HISTCONT ALL RTES	P=0.303	(e)	P=0.086	(e)



**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Liver  
Hemangiosarcoma**

**TUMOR RATES**

OVERALL (a)	2/50 (4%)	1/50 (2%)	4/50 (8%)	1/50 (2%)
POLY-3 RATE (b)	2/42.87	1/45.93	4/44	1/45.33
POLY-3 PERCENT (g)	4.7%	2.2%	9.1%	2.2%
TERMINAL (d)	2/31 (7%)	0/38 (0%)	1/32 (3%)	1/37 (3%)
FIRST INCIDENCE	729 (T)	684	590	729 (T)
HC TUMORS SAME RTE	10/299 (3%)			
HC TUMORS ALL RTES	29/1096 (3%)			

**STATISTICAL TESTS**

POLY 3	P=0.480N	P=0.476N	P=0.349	P=0.481N
POLY 1.5	P=0.487N	P=0.487N	P=0.343	P=0.489N
POLY 6	P=0.471N	P=0.460N	P=0.360	P=0.468N
COCH-ARM / FISHERS	P=0.495N	P=0.500N	P=0.339	P=0.500N
MAX-ISO-POLY-3	P=0.405N	P=0.267N	P=0.212	P=0.270N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

---

TDMS No. 99017 - 06  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Diethylamine  
 CAS Number: 109-89-7

Date Report Requested: 10/23/2008  
 Time Report Requested: 13:20:12  
 First Dose M/F: 08/18/03 / 08/18/03  
 Lab: BNW

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

Liver  
 Hepatocellular Adenoma

**TUMOR RATES**

OVERALL (a)	28/50 (56%)	29/50 (58%)	28/50 (56%)	31/50 (62%)
POLY-3 RATE (b)	28/46.08	29/47.71	28/44.28	31/48.75
POLY-3 PERCENT (g)	60.8%	60.8%	63.2%	63.6%
TERMINAL (d)	21/31 (68%)	23/38 (61%)	25/32 (78%)	23/37 (62%)
FIRST INCIDENCE	491	484	551	442
HC TUMORS SAME RTE	141/299 (47%)			
HC TUMORS ALL RTES	537/1096 (49%)			

**STATISTICAL TESTS**

POLY 3	P=0.408	P=0.585	P=0.490	P=0.471
POLY 1.5	P=0.365	P=0.547	P=0.527	P=0.414
POLY 6	P=0.468	P=0.535N	P=0.444	P=0.548
COCH-ARM / FISHERS	P=0.313	P=0.500	P=0.580N	P=0.342
MAX-ISO-POLY-3	P=0.607	P=0.499	P=0.401	P=0.388
HISTCONT SAME RTE	P=0.133	P=0.303	P=0.265	P=0.232
HISTCONT ALL RTES	P=0.222	P=0.399	P=0.358	P=0.324

---

TDMS No. 99017 - 06  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Diethylamine  
 CAS Number: 109-89-7

Date Report Requested: 10/23/2008  
 Time Report Requested: 13:20:12  
 First Dose M/F: 08/18/03 / 08/18/03  
 Lab: BNW

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Liver  
 Hepatocellular Carcinoma**

**TUMOR RATES**

OVERALL (a)	20/50 (40%)	17/50 (34%)	14/50 (28%)	20/50 (40%)
POLY-3 RATE (b)	20/46.58	17/47.91	14/45.42	20/47.65
POLY-3 PERCENT (g)	42.9%	35.5%	30.8%	42%
TERMINAL (d)	10/31 (32%)	11/38 (29%)	8/32 (25%)	12/37 (32%)
FIRST INCIDENCE	491	536	484	563
HC TUMORS SAME RTE	74/299 (25%)			
HC TUMORS ALL RTES	313/1096 (29%)			

**STATISTICAL TESTS**

POLY 3	P=0.522	P=0.297N	P=0.159N	P=0.545N
POLY 1.5	P=0.513	P=0.317N	P=0.155N	P=0.564N
POLY 6	P=0.541	P=0.268N	P=0.162N	P=0.510N
COCH-ARM / FISHERS	P=0.509	P=0.339N	P=0.146N	P=0.581N
MAX-ISO-POLY-3	P=0.404N	P=0.232N	P=0.115N	P=0.461N
HISTCONT SAME RTE	P=0.050*	P=0.235	P=0.420	P=0.112
HISTCONT ALL RTES	P=0.159	P=0.397	P=0.591	P=0.191

TDMS No. 99017 - 06  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Diethylamine  
 CAS Number: 109-89-7

Date Report Requested: 10/23/2008  
 Time Report Requested: 13:20:12  
 First Dose M/F: 08/18/03 / 08/18/03  
 Lab: BNW

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Liver  
 Hepatocellular Carcinoma or Hepatoblastoma**

**TUMOR RATES**

OVERALL (a)	20/50 (40%)	17/50 (34%)	14/50 (28%)	20/50 (40%)
POLY-3 RATE (b)	20/46.58	17/47.91	14/45.42	20/47.65
POLY-3 PERCENT (g)	42.9%	35.5%	30.8%	42%
TERMINAL (d)	10/31 (32%)	11/38 (29%)	8/32 (25%)	12/37 (32%)
FIRST INCIDENCE	491	536	484	563
HC TUMORS SAME RTE	75/299 (25%)			
HC TUMORS ALL RTES	342/1096 (31%)			

**STATISTICAL TESTS**

POLY 3	P=0.522	P=0.297N	P=0.159N	P=0.545N
POLY 1.5	P=0.513	P=0.317N	P=0.155N	P=0.564N
POLY 6	P=0.541	P=0.268N	P=0.162N	P=0.510N
COCH-ARM / FISHERS	P=0.509	P=0.339N	P=0.146N	P=0.581N
MAX-ISO-POLY-3	P=0.404N	P=0.232N	P=0.115N	P=0.461N
HISTCONT SAME RTE	P=0.054	P=0.244	P=0.433	P=0.115
HISTCONT ALL RTES	P=0.391	P=0.521	P=1.000	P=0.302

TDMS No. 99017 - 06  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Diethylamine  
 CAS Number: 109-89-7

Date Report Requested: 10/23/2008  
 Time Report Requested: 13:20:12  
 First Dose M/F: 08/18/03 / 08/18/03  
 Lab: BNW

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Liver  
 Hepatocellular Carcinoma or Hepatocellular Adenoma**

**TUMOR RATES**

OVERALL (a)	40/50 (80%)	37/50 (74%)	36/50 (72%)	38/50 (76%)
POLY-3 RATE (b)	40/48.12	37/49.04	36/46.5	38/49.81
POLY-3 PERCENT (g)	83.1%	75.5%	77.4%	76.3%
TERMINAL (d)	26/31 (84%)	27/38 (71%)	27/32 (84%)	26/37 (70%)
FIRST INCIDENCE	491	484	484	442
HC TUMORS SAME RTE	185/299 (62%)			
HC TUMORS ALL RTES	719/1096 (66%)			

**STATISTICAL TESTS**

POLY 3	P=0.302N	P=0.242N	P=0.322N	P=0.274N
POLY 1.5	P=0.346N	P=0.274N	P=0.288N	P=0.329N
POLY 6	P=0.247N	P=0.199N	P=0.364N	P=0.208N
COCH-ARM / FISHERS	P=0.402N	P=0.318N	P=0.241N	P=0.405N
MAX-ISO-POLY-3	P=0.330N	P=0.172N	P=0.235N	P=0.201N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

Liver  
Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma

**TUMOR RATES**

OVERALL (a)	40/50 (80%)	37/50 (74%)	36/50 (72%)	38/50 (76%)
POLY-3 RATE (b)	40/48.12	37/49.04	36/46.5	38/49.81
POLY-3 PERCENT (g)	83.1%	75.5%	77.4%	76.3%
TERMINAL (d)	26/31 (84%)	27/38 (71%)	27/32 (84%)	26/37 (70%)
FIRST INCIDENCE	491	484	484	442
HC TUMORS SAME RTE	186/299 (62%)			
HC TUMORS ALL RTES	730/1096 (67%)			

**STATISTICAL TESTS**

POLY 3	P=0.302N	P=0.242N	P=0.322N	P=0.274N
POLY 1.5	P=0.346N	P=0.274N	P=0.288N	P=0.329N
POLY 6	P=0.247N	P=0.199N	P=0.364N	P=0.208N
COCH-ARM / FISHERS	P=0.402N	P=0.318N	P=0.241N	P=0.405N
MAX-ISO-POLY-3	P=0.330N	P=0.172N	P=0.235N	P=0.201N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99017 - 06  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Diethylamine  
 CAS Number: 109-89-7

Date Report Requested: 10/23/2008  
 Time Report Requested: 13:20:12  
 First Dose M/F: 08/18/03 / 08/18/03  
 Lab: BNW

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Lung  
 Alveolar/Bronchiolar Adenoma**

**TUMOR RATES**

OVERALL (a)	4/50 (8%)	4/50 (8%)	5/50 (10%)	3/50 (6%)
POLY-3 RATE (b)	4/42.87	4/46.54	5/44.78	3/45.94
POLY-3 PERCENT (g)	9.3%	8.6%	11.2%	6.5%
TERMINAL (d)	4/31 (13%)	2/38 (5%)	2/32 (6%)	1/37 (3%)
FIRST INCIDENCE	729 (T)	484	442	554
HC TUMORS SAME RTE	58/299 (19%)			
HC TUMORS ALL RTES	198/1098 (18%)			

**STATISTICAL TESTS**

POLY 3	P=0.400N	P=0.598N	P=0.527	P=0.462N
POLY 1.5	P=0.413N	P=0.617N	P=0.515	P=0.479N
POLY 6	P=0.382N	P=0.570N	P=0.545	P=0.438N
COCH-ARM / FISHERS	P=0.429N	P=0.643N	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.493N	P=0.452N	P=0.390	P=0.319N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99017 - 06  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Diethylamine  
 CAS Number: 109-89-7

Date Report Requested: 10/23/2008  
 Time Report Requested: 13:20:12  
 First Dose M/F: 08/18/03 / 08/18/03  
 Lab: BNW

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Lung  
 Alveolar/Bronchiolar Carcinoma**

**TUMOR RATES**

OVERALL (a)	12/50 (24%)	10/50 (20%)	10/50 (20%)	9/50 (18%)
POLY-3 RATE (b)	12/45.28	10/46.53	10/44.17	9/45.94
POLY-3 PERCENT (g)	26.5%	21.5%	22.6%	19.6%
TERMINAL (d)	6/31 (19%)	8/38 (21%)	7/32 (22%)	7/37 (19%)
FIRST INCIDENCE	503	561	506	555
HC TUMORS SAME RTE	38/299 (13%)			
HC TUMORS ALL RTES	109/1098 (10%)			

**STATISTICAL TESTS**

POLY 3	P=0.283N	P=0.375N	P=0.429N	P=0.296N
POLY 1.5	P=0.285N	P=0.389N	P=0.420N	P=0.304N
POLY 6	P=0.280N	P=0.357N	P=0.440N	P=0.286N
COCH-ARM / FISHERS	P=0.287N	P=0.405N	P=0.405N	P=0.312N
MAX-ISO-POLY-3	P=0.350N	P=0.290N	P=0.337N	P=0.218N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)



**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Lung  
Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma**

**TUMOR RATES**

OVERALL (a)	15/50 (30%)	14/50 (28%)	14/50 (28%)	12/50 (24%)
POLY-3 RATE (b)	15/45.28	14/47.32	14/45.76	12/46.55
POLY-3 PERCENT (g)	33.1%	29.6%	30.6%	25.8%
TERMINAL (d)	9/31 (29%)	10/38 (26%)	8/32 (25%)	8/37 (22%)
FIRST INCIDENCE	503	484	442	554
HC TUMORS SAME RTE	92/299 (31%)			
HC TUMORS ALL RTES	295/1098 (27%)			

**STATISTICAL TESTS**

POLY 3	P=0.269N	P=0.443N	P=0.486N	P=0.293N
POLY 1.5	P=0.277N	P=0.467N	P=0.492N	P=0.308N
POLY 6	P=0.257N	P=0.412N	P=0.479N	P=0.274N
COCH-ARM / FISHERS	P=0.287N	P=0.500N	P=0.500N	P=0.326N
MAX-ISO-POLY-3	P=0.363N	P=0.358N	P=0.396N	P=0.223N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

---

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>Mammary Gland Carcinoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	0/45.75	0/43.2	0/45.33
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME RTE	0/300 (0%)			
HC TUMORS ALL RTES	1/1099 (0%)			

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Mammary Gland  
Fibroma, Fibroadenoma, Carcinoma, or Adenoma**

---

TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	0/45.75	0/43.2	0/45.33
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME RTE	0/300 (0%)			
HC TUMORS ALL RTES	1/1099 (0%)			

**STATISTICAL TESTS**

---

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

---

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>Mesentery Hemangiosarcoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	3/50 (6%)
POLY-3 RATE (b)	1/42.87	0/45.75	0/43.2	3/45.33
POLY-3 PERCENT (g)	2.3%	0%	0%	6.6%
TERMINAL (d)	1/31 (3%)	0/38 (0%)	0/32 (0%)	3/37 (8%)
FIRST INCIDENCE	729 (T)	---	---	729 (T)
HC TUMORS SAME RTE	0/300 (0%)			
HC TUMORS ALL RTES	1/1099 (0%)			

**STATISTICAL TESTS**

POLY 3	P=0.084	P=0.487N	P=0.498N	P=0.325
POLY 1.5	P=0.085	P=0.493N	P=0.500N	P=0.316
POLY 6	P=0.084	P=0.479N	P=0.496N	P=0.339
COCH-ARM / FISHERS	P=0.086	P=0.500N	P=0.500N	P=0.309
MAX-ISO-POLY-3	P=0.054	P=0.158N	P=0.158N	P=0.175
HISTCONT SAME RTE	P=0.016*	(e)	(e)	P=0.023*
HISTCONT ALL RTES	P<0.001**	(e)	(e)	P<0.001**

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Pituitary Gland: Pars Distalis or Unspecified Site  
Adenoma**

**TUMOR RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	0/45.75	0/42.59	0/45.33
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME RTE	1/290 (0%)			
HC TUMORS ALL RTES	3/1070 (0%)			

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Pituitary Gland: Pars Distalis or Unspecified Site  
Carcinoma or Adenoma**

**TUMOR RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	0/45.75	0/42.59	0/45.33
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME RTE	1/290 (0%)			
HC TUMORS ALL RTES	4/1070 (0%)			

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

---

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Pituitary Gland: Pars Intermedia  
Adenoma**

**TUMOR RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	0/45.75	0/42.59	0/45.33
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME RTE	1/290 (0%)			
HC TUMORS ALL RTES	3/1070 (0%)			

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

---

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>Skeletal Muscle Hemangiosarcoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	0/50 (0%)	1/50 (2%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	1/45.8	2/43.68	0/45.33
POLY-3 PERCENT (g)	0%	2.2%	4.6%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	---	718	618	---
HC TUMORS SAME RTE	0/300 (0%)			
HC TUMORS ALL RTES	2/1099 (0%)			

**STATISTICAL TESTS**

POLY 3	P=0.596N	P=0.513	P=0.241	(e)
POLY 1.5	P=0.605N	P=0.507	P=0.239	(e)
POLY 6	P=0.584N	P=0.522	P=0.245	(e)
COCH-ARM / FISHERS	P=0.615N	P=0.500	P=0.247	(e)
MAX-ISO-POLY-3	P=0.342N	P=0.175	P=0.080	(e)
HISTCONT SAME RTE	(h)	(h)	(h)	(e)
HISTCONT ALL RTES	(h)	(h)	(h)	(e)



**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Skin  
Fibroma, Fibrosarcoma, Sarcoma, Myxoma, Myxosarcoma, or Fibrous Histiocytoma**

TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	2/50 (4%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	1/42.87	2/45.99	1/43.2	1/45.33
POLY-3 PERCENT (g)	2.3%	4.4%	2.3%	2.2%
TERMINAL (d)	1/31 (3%)	1/38 (3%)	1/32 (3%)	1/37 (3%)
FIRST INCIDENCE	729 (T)	666	729 (T)	729 (T)
HC TUMORS SAME RTE	7/300 (2%)			
HC TUMORS ALL RTES	13/1099 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.520N	P=0.524	P=0.759N	P=0.748N
POLY 1.5	P=0.527N	P=0.513	P=0.760N	P=0.754N
POLY 6	P=0.511N	P=0.540	P=0.757N	P=0.740N
COCH-ARM / FISHERS	P=0.534N	P=0.500	P=0.753N	P=0.753N
MAX-ISO-POLY-3	P=0.588N	P=0.307	P=0.497N	P=0.484N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Skin  
Fibrosarcoma, Sarcoma, Myxosarcoma, or Fibrous Histiocytoma**

TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	2/50 (4%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	1/42.87	2/45.99	0/43.2	1/45.33
POLY-3 PERCENT (g)	2.3%	4.4%	0%	2.2%
TERMINAL (d)	1/31 (3%)	1/38 (3%)	0/32 (0%)	1/37 (3%)
FIRST INCIDENCE	729 (T)	666	---	729 (T)
HC TUMORS SAME RTE	7/300 (2%)			
HC TUMORS ALL RTES	10/1099 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.497N	P=0.524	P=0.498N	P=0.748N
POLY 1.5	P=0.502N	P=0.513	P=0.500N	P=0.754N
POLY 6	P=0.490N	P=0.540	P=0.496N	P=0.740N
COCH-ARM / FISHERS	P=0.507N	P=0.500	P=0.500N	P=0.753N
MAX-ISO-POLY-3	P=0.398N	P=0.307	P=0.158N	P=0.484N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>Skin</b>				
<b>Fibrous Histiocytoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	0/50 (0%)	2/50 (4%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/42.87	2/45.99	0/43.2	1/45.33
POLY-3 PERCENT (g)	0%	4.4%	0%	2.2%
TERMINAL (d)	0/31 (0%)	1/38 (3%)	0/32 (0%)	1/37 (3%)
FIRST INCIDENCE	---	666	---	729 (T)
HC TUMORS SAME RTE	4/300 (1%)			
HC TUMORS ALL RTES	5/1099 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.557	P=0.253	(e)	P=0.511
POLY 1.5	P=0.546	P=0.246	(e)	P=0.506
POLY 6	P=0.572	P=0.264	(e)	P=0.518
COCH-ARM / FISHERS	P=0.534	P=0.247	(e)	P=0.500
MAX-ISO-POLY-3	P=0.349	P=0.091	(e)	P=0.172
HISTCONT SAME RTE	P=0.420	P=0.110	(e)	P=0.217
HISTCONT ALL RTES	P=0.261	P=0.021*	(e)	P=0.175

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>Skin</b>				
<b>Sarcoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/42.87	0/45.75	0/43.2	0/45.33
POLY-3 PERCENT (g)	2.3%	0%	0%	0%
TERMINAL (d)	1/31 (3%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	729 (T)	---	---	---
HC TUMORS SAME RTE	3/300 (1%)			
HC TUMORS ALL RTES	5/1099 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.319N	P=0.487N	P=0.498N	P=0.489N
POLY 1.5	P=0.313N	P=0.493N	P=0.500N	P=0.494N
POLY 6	P=0.326N	P=0.479N	P=0.496N	P=0.482N
COCH-ARM / FISHERS	P=0.307N	P=0.500N	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.123N	P=0.158N	P=0.158N	P=0.158N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99017 - 06  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Diethylamine  
 CAS Number: 109-89-7

Date Report Requested: 10/23/2008  
 Time Report Requested: 13:20:12  
 First Dose M/F: 08/18/03 / 08/18/03  
 Lab: BNW

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Spleen  
 Hemangiosarcoma**

**TUMOR RATES**

OVERALL (a)	3/50 (6%)	4/50 (8%)	4/49 (8%)	1/50 (2%)
POLY-3 RATE (b)	3/43.32	4/46.05	4/43.33	1/45.33
POLY-3 PERCENT (g)	6.9%	8.7%	9.2%	2.2%
TERMINAL (d)	1/31 (3%)	1/38 (3%)	2/32 (6%)	1/37 (3%)
FIRST INCIDENCE	632	684	590	729 (T)
HC TUMORS SAME RTE	4/297 (1%)			
HC TUMORS ALL RTES	20/1086 (2%)			

**STATISTICAL TESTS**

POLY 3	P=0.197N	P=0.533	P=0.500	P=0.289N
POLY 1.5	P=0.204N	P=0.518	P=0.494	P=0.296N
POLY 6	P=0.188N	P=0.555	P=0.509	P=0.279N
COCH-ARM / FISHERS	P=0.212N	P=0.500	P=0.489	P=0.309N
MAX-ISO-POLY-3	P=0.215N	P=0.381	P=0.347	P=0.148N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Stomach, Forestomach  
Squamous Cell Carcinoma**

**TUMOR RATES**

	#	#	#	#
OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/42.87	0/45.75	0/43.2	0/45.33
POLY-3 PERCENT (g)	4.7%	0%	0%	0%
TERMINAL (d)	2/31 (7%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	729 (T)	---	---	---
HC TUMORS SAME RTE	0/300 (0%)			
HC TUMORS ALL RTES	3/1099 (0%)			

**STATISTICAL TESTS**

POLY 3	P=0.120N	P=0.223N	P=0.235N	P=0.225N
POLY 1.5	P=0.117N	P=0.229N	P=0.237N	P=0.230N
POLY 6	P=0.125N	P=0.214N	P=0.233N	P=0.217N
COCH-ARM / FISHERS	P=0.115N	P=0.247N	P=0.247N	P=0.247N
MAX-ISO-POLY-3	P=0.032N*	P=0.076N	P=0.076N	P=0.076N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Stomach, Forestomach  
Squamous Cell Carcinoma or Papilloma Squamous**

TUMOR RATES	#	#	#	#
OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	2/42.87	0/45.75	0/43.2	1/45.33
POLY-3 PERCENT (g)	4.7%	0%	0%	2.2%
TERMINAL (d)	2/31 (7%)	0/38 (0%)	0/32 (0%)	1/37 (3%)
FIRST INCIDENCE	729 (T)	---	---	729 (T)
HC TUMORS SAME RTE	2/300 (1%)			
HC TUMORS ALL RTES	13/1099 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.473N	P=0.223N	P=0.235N	P=0.481N
POLY 1.5	P=0.468N	P=0.229N	P=0.237N	P=0.489N
POLY 6	P=0.481N	P=0.214N	P=0.233N	P=0.468N
COCH-ARM / FISHERS	P=0.461N	P=0.247N	P=0.247N	P=0.500N
MAX-ISO-POLY-3	P=0.131N	P=0.076N	P=0.076N	P=0.270N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Thyroid Gland: Follicular Cell Adenoma**

**TUMOR RATES**

OVERALL (a)	0/50 (0%)	2/50 (4%)	0/48 (0%)	0/49 (0%)
POLY-3 RATE (b)	0/42.87	2/45.75	0/41.44	0/44.33
POLY-3 PERCENT (g)	0%	4.4%	0%	0%
TERMINAL (d)	0/31 (0%)	2/38 (5%)	0/31 (0%)	0/36 (0%)
FIRST INCIDENCE	---	729 (T)	---	---
HC TUMORS SAME RTE	4/297 (1%)			
HC TUMORS ALL RTES	19/1092 (2%)			

**STATISTICAL TESTS**

POLY 3	P=0.401N	P=0.252	(e)	(e)
POLY 1.5	P=0.410N	P=0.245	(e)	(e)
POLY 6	P=0.389N	P=0.262	(e)	(e)
COCH-ARM / FISHERS	P=0.420N	P=0.247	(e)	(e)
MAX-ISO-POLY-3	P=0.267N	P=0.090	(e)	(e)
HISTCONT SAME RTE	(h)	(h)	(e)	(e)
HISTCONT ALL RTES	(h)	(h)	(e)	(e)

---



**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>Tooth Odontoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	2/50 (4%)	3/50 (6%)	3/50 (6%)	0/50 (0%)
POLY-3 RATE (b)	2/43.26	3/45.83	3/43.22	0/45.33
POLY-3 PERCENT (g)	4.6%	6.6%	6.9%	0%
TERMINAL (d)	1/31 (3%)	2/38 (5%)	2/32 (6%)	0/37 (0%)
FIRST INCIDENCE	620	710	723	---
HC TUMORS SAME RTE	0/300 (0%)			
HC TUMORS ALL RTES	2/1099 (0%)			

**STATISTICAL TESTS**

POLY 3	P=0.153N	P=0.526	P=0.500	P=0.227N
POLY 1.5	P=0.158N	P=0.515	P=0.499	P=0.232N
POLY 6	P=0.145N	P=0.543	P=0.502	P=0.220N
COCH-ARM / FISHERS	P=0.165N	P=0.500	P=0.500	P=0.247N
MAX-ISO-POLY-3	P=0.143N	P=0.351	P=0.323	P=0.076N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>All Organs</b>				
<b>Hemangiosarcoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	7/50 (14%)	4/50 (8%)	6/50 (12%)	4/50 (8%)
POLY-3 RATE (b)	7/43.53	4/46.05	6/44.39	4/45.33
POLY-3 PERCENT (g)	16.1%	8.7%	13.5%	8.8%
TERMINAL (d)	4/31 (13%)	1/38 (3%)	2/32 (6%)	4/37 (11%)
FIRST INCIDENCE	632	684	590	729 (T)
HC TUMORS SAME RTE	16/300 (5%)			
HC TUMORS ALL RTES	65/1099 (6%)			

**STATISTICAL TESTS**

POLY 3	P=0.267N	P=0.229N	P=0.485N	P=0.237N
POLY 1.5	P=0.271N	P=0.243N	P=0.493N	P=0.248N
POLY 6	P=0.261N	P=0.210N	P=0.471N	P=0.223N
COCH-ARM / FISHERS	P=0.277N	P=0.262N	P=0.500N	P=0.262N
MAX-ISO-POLY-3	P=0.242N	P=0.149N	P=0.368N	P=0.154N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>All Organs</b>				
<b>Histiocytic Sarcoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	1/50 (2%)	2/50 (4%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	1/43.42	2/46.17	1/43.2	1/45.38
POLY-3 PERCENT (g)	2.3%	4.3%	2.3%	2.2%
TERMINAL (d)	0/31 (0%)	1/38 (3%)	1/32 (3%)	0/37 (0%)
FIRST INCIDENCE	561	610	729 (T)	715
HC TUMORS SAME RTE	3/300 (1%)			
HC TUMORS ALL RTES	6/1099 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.524N	P=0.521	P=0.760	P=0.751N
POLY 1.5	P=0.529N	P=0.512	P=0.760	P=0.755N
POLY 6	P=0.517N	P=0.535	P=0.761	P=0.744N
COCH-ARM / FISHERS	P=0.534N	P=0.500	P=0.753N	P=0.753N
MAX-ISO-POLY-3	P=0.590N	P=0.304	P=0.498	P=0.487N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**All Organs**  
**Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed, NOS, or Undifferentiated Cell Type**

---

TUMOR RATES	#	#	#	#
OVERALL (a)	2/50 (4%)	3/50 (6%)	3/50 (6%)	0/50 (0%)
POLY-3 RATE (b)	2/43.35	3/45.93	3/43.86	0/45.33
POLY-3 PERCENT (g)	4.6%	6.5%	6.8%	0%
TERMINAL (d)	1/31 (3%)	2/38 (5%)	2/32 (6%)	0/37 (0%)
FIRST INCIDENCE	589	684	508	---
HC TUMORS SAME RTE	8/300 (3%)			
HC TUMORS ALL RTES	32/1099 (3%)			

**STATISTICAL TESTS**

---

POLY 3	P=0.153N	P=0.526	P=0.505	P=0.227N
POLY 1.5	P=0.159N	P=0.514	P=0.502	P=0.232N
POLY 6	P=0.146N	P=0.544	P=0.510	P=0.221N
COCH-ARM / FISHERS	P=0.165N	P=0.500	P=0.500	P=0.247N
MAX-ISO-POLY-3	P=0.145N	P=0.351	P=0.329	P=0.076N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

---

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>All Organs</b>				
<b>Benign Tumors</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	33/50 (66%)	34/50 (68%)	34/50 (68%)	34/50 (68%)
POLY-3 RATE (b)	33/46.74	34/48.13	34/45.73	34/48.81
POLY-3 PERCENT (g)	70.6%	70.7%	74.3%	69.7%
TERMINAL (d)	24/31 (77%)	27/38 (71%)	27/32 (84%)	25/37 (68%)
FIRST INCIDENCE	491	484	442	442
HC TUMORS SAME RTE	200/300 (67%)			
HC TUMORS ALL RTES	730/1099 (66%)			

**STATISTICAL TESTS**

POLY 3	P=0.513N	P=0.590	P=0.430	P=0.549N
POLY 1.5	P=0.532	P=0.551	P=0.461	P=0.576
POLY 6	P=0.460N	P=0.545N	P=0.387	P=0.486N
COCH-ARM / FISHERS	P=0.470	P=0.500	P=0.500	P=0.500
MAX-ISO-POLY-3	P=0.631N	P=0.498	P=0.337	P=0.458N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>All Organs</b>				
<b>Malignant Tumors</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	36/50 (72%)	34/50 (68%)	32/50 (64%)	32/50 (64%)
POLY-3 RATE (b)	36/48.86	34/50	32/49.21	32/48.99
POLY-3 PERCENT (g)	73.7%	68%	65%	65.3%
TERMINAL (d)	20/31 (65%)	22/38 (58%)	17/32 (53%)	22/37 (60%)
FIRST INCIDENCE	491	484	442	442
HC TUMORS SAME RTE	146/300 (49%)			
HC TUMORS ALL RTES	562/1099 (51%)			

**STATISTICAL TESTS**

POLY 3	P=0.230N	P=0.344N	P=0.237N	P=0.247N
POLY 1.5	P=0.228N	P=0.375N	P=0.248N	P=0.253N
POLY 6	P=0.233N	P=0.304N	P=0.221N	P=0.238N
COCH-ARM / FISHERS	P=0.224N	P=0.414N	P=0.260N	P=0.260N
MAX-ISO-POLY-3	P=0.297N	P=0.270N	P=0.176N	P=0.183N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**All Organs  
Malignant and Benign Tumors**

**TUMOR RATES**

	#	#	#	#
OVERALL (a)	48/50 (96%)	46/50 (92%)	47/50 (94%)	44/50 (88%)
POLY-3 RATE (b)	48/50	46/50	47/49.8	44/49.81
POLY-3 PERCENT (g)	96%	92%	94.4%	88.3%
TERMINAL (d)	29/31 (94%)	34/38 (90%)	30/32 (94%)	32/37 (87%)
FIRST INCIDENCE	491	484	442	442
HC TUMORS SAME RTE	259/300 (86%)			
HC TUMORS ALL RTES	944/1099 (86%)			

**STATISTICAL TESTS**

POLY 3	P=0.121N	P=0.338N	P=0.535N	P=0.144N
POLY 1.5	P=0.115N	P=0.338N	P=0.518N	P=0.139N
POLY 6	P=0.131N	P=0.338N	P=0.564N	P=0.153N
COCH-ARM / FISHERS	P=0.109N	P=0.339N	P=0.500N	P=0.134N
MAX-ISO-POLY-3	P=0.109N	P=0.202N	P=0.350N	P=0.075N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

---

TDMS No. 99017 - 06  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Diethylamine  
 CAS Number: 109-89-7

Date Report Requested: 10/23/2008  
 Time Report Requested: 13:20:12  
 First Dose M/F: 08/18/03 / 08/18/03  
 Lab: BNW

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Adrenal Cortex  
 Adenoma**

**TUMOR RATES**

OVERALL (a)	1/50 (2%)	2/50 (4%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	1/43.5	2/43.3	0/47.59	2/47.37
POLY-3 PERCENT (g)	2.3%	4.6%	0%	4.2%
TERMINAL (d)	1/32 (3%)	2/35 (6%)	0/36 (0%)	2/39 (5%)
FIRST INCIDENCE	731 (T)	731 (T)	---	731 (T)
HC TUMORS SAME RTE	2/299 (1%)			
HC TUMORS ALL RTES	5/1194 (0%)			

**STATISTICAL TESTS**

POLY 3	P=0.495	P=0.498	P=0.482N	P=0.530
POLY 1.5	P=0.486	P=0.501	P=0.488N	P=0.521
POLY 6	P=0.505	P=0.496	P=0.475N	P=0.539
COCH-ARM / FISHERS	P=0.466	P=0.500	P=0.500N	P=0.500
MAX-ISO-POLY-3	P=0.465	P=0.279	P=0.158N	P=0.313
HISTCONT SAME RTE	P=0.145	P=0.066	(e)	P=0.062
HISTCONT ALL RTES	P=0.012*	P=0.010**	(e)	P=0.010**



**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Adrenal Medulla  
Pheochromocytoma: Benign, Complex, Malignant, NOS**

**TUMOR RATES**

OVERALL (a)	0/50 (0%)	2/50 (4%)	1/50 (2%)	1/49 (2%)
POLY-3 RATE (b)	0/43.5	2/43.3	1/47.59	1/46.41
POLY-3 PERCENT (g)	0%	4.6%	2.1%	2.2%
TERMINAL (d)	0/32 (0%)	2/35 (6%)	1/36 (3%)	0/38 (0%)
FIRST INCIDENCE	---	731 (T)	731 (T)	719
HC TUMORS SAME RTE	7/296 (2%)			
HC TUMORS ALL RTES	22/1189 (2%)			

**STATISTICAL TESTS**

POLY 3	P=0.532	P=0.236	P=0.518	P=0.513
POLY 1.5	P=0.519	P=0.238	P=0.512	P=0.508
POLY 6	P=0.545	P=0.235	P=0.525	P=0.519
COCH-ARM / FISHERS	P=0.492	P=0.247	P=0.500	P=0.495
MAX-ISO-POLY-3	P=0.297	P=0.076	P=0.180	P=0.176
HISTCONT SAME RTE	P=0.359	P=0.091	P=0.228	P=0.221
HISTCONT ALL RTES	P=0.345	P=0.086	P=0.217	P=0.210

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>Bone Marrow Hemangiosarcoma</b>				
<b>TUMOR RATES</b>				
OVERALL (a)	1/50 (2%)	1/50 (2%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/43.95	1/43.3	0/47.59	0/47.37
POLY-3 PERCENT (g)	2.3%	2.3%	0%	0%
TERMINAL (d)	0/32 (0%)	1/35 (3%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	599	731 (T)	---	---
HC TUMORS SAME RTE	2/297 (1%)			
HC TUMORS ALL RTES	7/1193 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.234N	P=0.757	P=0.484N	P=0.485N
POLY 1.5	P=0.236N	P=0.760	P=0.489N	P=0.489N
POLY 6	P=0.232N	P=0.755	P=0.478N	P=0.481N
COCH-ARM / FISHERS	P=0.239N	P=0.753N	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.252N	P=0.495	P=0.158N	P=0.158N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>Harderian Gland Adenoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	3/50 (6%)	1/50 (2%)	0/50 (0%)	5/50 (10%)
POLY-3 RATE (b)	3/43.5	1/43.3	0/47.59	5/47.83
POLY-3 PERCENT (g)	6.9%	2.3%	0%	10.5%
TERMINAL (d)	3/32 (9%)	1/35 (3%)	0/36 (0%)	3/39 (8%)
FIRST INCIDENCE	731 (T)	731 (T)	---	610
HC TUMORS SAME RTE	29/300 (10%)			
HC TUMORS ALL RTES	125/1199 (10%)			

**STATISTICAL TESTS**

POLY 3	P=0.180	P=0.307N	P=0.103N	P=0.410
POLY 1.5	P=0.173	P=0.304N	P=0.109N	P=0.393
POLY 6	P=0.187	P=0.308N	P=0.098N	P=0.430
COCH-ARM / FISHERS	P=0.163	P=0.309N	P=0.121N	P=0.357
MAX-ISO-POLY-3	P=0.088	P=0.155N	P=0.038N*	P=0.285
HISTCONT SAME RTE	P=0.103	P=1.000	(e)	P=0.368
HISTCONT ALL RTES	P=0.099	P=1.000	(e)	P=0.355

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>Harderian Gland Carcinoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	2/50 (4%)	1/50 (2%)	0/50 (0%)	4/50 (8%)
POLY-3 RATE (b)	2/43.6	1/43.3	0/47.59	4/47.37
POLY-3 PERCENT (g)	4.6%	2.3%	0%	8.5%
TERMINAL (d)	0/32 (0%)	1/35 (3%)	0/36 (0%)	4/39 (10%)
FIRST INCIDENCE	712	731 (T)	---	731 (T)
HC TUMORS SAME RTE	10/300 (3%)			
HC TUMORS ALL RTES	32/1199 (3%)			

**STATISTICAL TESTS**

POLY 3	P=0.179	P=0.502N	P=0.218N	P=0.376
POLY 1.5	P=0.174	P=0.500N	P=0.225N	P=0.365
POLY 6	P=0.185	P=0.505N	P=0.211N	P=0.389
COCH-ARM / FISHERS	P=0.164	P=0.500N	P=0.247N	P=0.339
MAX-ISO-POLY-3	P=0.108	P=0.283N	P=0.076N	P=0.241
HISTCONT SAME RTE	P=0.129	P=1.000	(e)	P=0.215
HISTCONT ALL RTES	P=0.113	P=1.000	(e)	P=0.079

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>Harderian Gland Carcinoma or Adenoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	5/50 (10%)	2/50 (4%)	0/50 (0%)	9/50 (18%)
POLY-3 RATE (b)	5/43.6	2/43.3	0/47.59	9/47.83
POLY-3 PERCENT (g)	11.5%	4.6%	0%	18.8%
TERMINAL (d)	3/32 (9%)	2/35 (6%)	0/36 (0%)	7/39 (18%)
FIRST INCIDENCE	712	731 (T)	---	610
HC TUMORS SAME RTE	38/300 (13%)			
HC TUMORS ALL RTES	156/1199 (13%)			

**STATISTICAL TESTS**

POLY 3	P=0.062	P=0.218N	P=0.024N*	P=0.248
POLY 1.5	P=0.058	P=0.215N	P=0.026N*	P=0.230
POLY 6	P=0.066	P=0.220N	P=0.021N*	P=0.268
COCH-ARM / FISHERS	P=0.056	P=0.218N	P=0.028N*	P=0.194
MAX-ISO-POLY-3	P=0.018*	P=0.121N	P=0.010N**	P=0.177
HISTCONT SAME RTE	P=0.020*	P=1.000	(e)	P=0.223
HISTCONT ALL RTES	P=0.019*	P=1.000	(e)	P=0.211

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Intestine Small: Jejunum  
Carcinoma**

**TUMOR RATES**

	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.5	0/43.3	0/47.59	0/47.37
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME RTE	0/300 (0%)			
HC TUMORS ALL RTES	4/1199 (0%)			

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Intestine Small: Site Unspecified  
Carcinoma**

TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.5	0/43.3	0/47.59	0/47.37
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME RTE	0/300 (0%)			
HC TUMORS ALL RTES	6/1199 (1%)			

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Islets, Pancreatic  
Adenoma**

**TUMOR RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/43.5	0/43.3	0/47.59	1/47.64
POLY-3 PERCENT (g)	0%	0%	0%	2.1%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	---	---	---	656
HC TUMORS SAME RTE	2/295 (1%)			
HC TUMORS ALL RTES	12/1178 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.214	(e)	(e)	P=0.518
POLY 1.5	P=0.209	(e)	(e)	P=0.512
POLY 6	P=0.219	(e)	(e)	P=0.525
COCH-ARM / FISHERS	P=0.200	(e)	(e)	P=0.500
MAX-ISO-POLY-3	P=0.155	(e)	(e)	P=0.181
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)



**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Islets, Pancreatic  
Carcinoma or Adenoma**

**TUMOR RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/43.5	0/43.3	0/47.59	1/47.64
POLY-3 PERCENT (g)	0%	0%	0%	2.1%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	---	---	---	656
HC TUMORS SAME RTE	4/295 (1%)			
HC TUMORS ALL RTES	16/1178 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.214	(e)	(e)	P=0.518
POLY 1.5	P=0.209	(e)	(e)	P=0.512
POLY 6	P=0.219	(e)	(e)	P=0.525
COCH-ARM / FISHERS	P=0.200	(e)	(e)	P=0.500
MAX-ISO-POLY-3	P=0.155	(e)	(e)	P=0.181
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Kidney: Renal Tubule  
Carcinoma or Adenoma**

**TUMOR RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.5	0/43.3	0/47.59	0/47.37
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME RTE	0/298 (0%)			
HC TUMORS ALL RTES	0/1190 (0%)			

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>Liver Hemangiosarcoma</b>				
<b>TUMOR RATES</b>				
OVERALL (a)	1/50 (2%)	1/50 (2%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/43.5	1/43.3	0/47.59	0/47.37
POLY-3 PERCENT (g)	2.3%	2.3%	0%	0%
TERMINAL (d)	1/32 (3%)	1/35 (3%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	731 (T)	731 (T)	---	---
HC TUMORS SAME RTE	2/299 (1%)			
HC TUMORS ALL RTES	11/1195 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.233N	P=0.760	P=0.482N	P=0.483N
POLY 1.5	P=0.235N	P=0.760N	P=0.488N	P=0.488N
POLY 6	P=0.231N	P=0.759	P=0.475N	P=0.477N
COCH-ARM / FISHERS	P=0.239N	P=0.753N	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.254N	P=0.498	P=0.158N	P=0.158N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Liver  
Hepatocellular Adenoma**

**TUMOR RATES**

OVERALL (a)	14/50 (28%)	19/50 (38%)	17/50 (34%)	10/50 (20%)
POLY-3 RATE (b)	14/44.59	19/45.31	17/47.93	10/47.98
POLY-3 PERCENT (g)	31.4%	41.9%	35.5%	20.8%
TERMINAL (d)	11/32 (34%)	14/35 (40%)	14/36 (39%)	7/39 (18%)
FIRST INCIDENCE	592	444	659	653
HC TUMORS SAME RTE	82/299 (27%)			
HC TUMORS ALL RTES	342/1195 (29%)			

**STATISTICAL TESTS**

POLY 3	P=0.070N	P=0.205	P=0.423	P=0.178N
POLY 1.5	P=0.085N	P=0.207	P=0.394	P=0.196N
POLY 6	P=0.056N	P=0.205	P=0.458	P=0.160N
COCH-ARM / FISHERS	P=0.127N	P=0.198	P=0.333	P=0.241N
MAX-ISO-POLY-3	P=0.087N	P=0.149	P=0.344	P=0.131N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99017 - 06  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Diethylamine  
 CAS Number: 109-89-7

Date Report Requested: 10/23/2008  
 Time Report Requested: 13:20:12  
 First Dose M/F: 08/18/03 / 08/18/03  
 Lab: BNW

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Liver  
 Hepatocellular Carcinoma**

**TUMOR RATES**

OVERALL (a)	4/50 (8%)	5/50 (10%)	7/50 (14%)	2/50 (4%)
POLY-3 RATE (b)	4/43.5	5/44.4	7/47.75	2/47.41
POLY-3 PERCENT (g)	9.2%	11.3%	14.7%	4.2%
TERMINAL (d)	4/32 (13%)	3/35 (9%)	6/36 (17%)	1/39 (3%)
FIRST INCIDENCE	731 (T)	533	689	719
HC TUMORS SAME RTE	34/299 (11%)			
HC TUMORS ALL RTES	129/1195 (11%)			

**STATISTICAL TESTS**

POLY 3	P=0.220N	P=0.513	P=0.317	P=0.298N
POLY 1.5	P=0.238N	P=0.510	P=0.298	P=0.310N
POLY 6	P=0.202N	P=0.518	P=0.342	P=0.285N
COCH-ARM / FISHERS	P=0.278N	P=0.500	P=0.262	P=0.339N
MAX-ISO-POLY-3	P=0.198N	P=0.375	P=0.224	P=0.181N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Liver  
Hepatocellular Carcinoma or Hepatoblastoma**

**TUMOR RATES**

OVERALL (a)	4/50 (8%)	5/50 (10%)	7/50 (14%)	2/50 (4%)
POLY-3 RATE (b)	4/43.5	5/44.4	7/47.75	2/47.41
POLY-3 PERCENT (g)	9.2%	11.3%	14.7%	4.2%
TERMINAL (d)	4/32 (13%)	3/35 (9%)	6/36 (17%)	1/39 (3%)
FIRST INCIDENCE	731 (T)	533	689	719
HC TUMORS SAME RTE	34/299 (11%)			
HC TUMORS ALL RTES	134/1195 (11%)			

**STATISTICAL TESTS**

POLY 3	P=0.220N	P=0.513	P=0.317	P=0.298N
POLY 1.5	P=0.238N	P=0.510	P=0.298	P=0.310N
POLY 6	P=0.202N	P=0.518	P=0.342	P=0.285N
COCH-ARM / FISHERS	P=0.278N	P=0.500	P=0.262	P=0.339N
MAX-ISO-POLY-3	P=0.198N	P=0.375	P=0.224	P=0.181N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Liver  
Hepatocellular Carcinoma or Hepatocellular Adenoma**

**TUMOR RATES**

OVERALL (a)	16/50 (32%)	23/50 (46%)	22/50 (44%)	11/50 (22%)
POLY-3 RATE (b)	16/44.59	23/46.41	22/48.09	11/47.98
POLY-3 PERCENT (g)	35.9%	49.6%	45.8%	22.9%
TERMINAL (d)	13/32 (41%)	16/35 (46%)	18/36 (50%)	8/39 (21%)
FIRST INCIDENCE	592	444	659	653
HC TUMORS SAME RTE	104/299 (35%)			
HC TUMORS ALL RTES	415/1195 (35%)			

**STATISTICAL TESTS**

POLY 3	P=0.037N*	P=0.131	P=0.224	P=0.125N
POLY 1.5	P=0.047N*	P=0.125	P=0.199	P=0.141N
POLY 6	P=0.028N*	P=0.141	P=0.258	P=0.109N
COCH-ARM / FISHERS	P=0.082N	P=0.109	P=0.151	P=0.184N
MAX-ISO-POLY-3	P=0.032N*	P=0.095	P=0.175	P=0.092N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

---

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Liver  
Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma**

**TUMOR RATES**

OVERALL (a)	16/50 (32%)	23/50 (46%)	22/50 (44%)	11/50 (22%)
POLY-3 RATE (b)	16/44.59	23/46.41	22/48.09	11/47.98
POLY-3 PERCENT (g)	35.9%	49.6%	45.8%	22.9%
TERMINAL (d)	13/32 (41%)	16/35 (46%)	18/36 (50%)	8/39 (21%)
FIRST INCIDENCE	592	444	659	653
HC TUMORS SAME RTE	104/299 (35%)			
HC TUMORS ALL RTES	417/1195 (35%)			

**STATISTICAL TESTS**

POLY 3	P=0.037N*	P=0.131	P=0.224	P=0.125N
POLY 1.5	P=0.047N*	P=0.125	P=0.199	P=0.141N
POLY 6	P=0.028N*	P=0.141	P=0.258	P=0.109N
COCH-ARM / FISHERS	P=0.082N	P=0.109	P=0.151	P=0.184N
MAX-ISO-POLY-3	P=0.032N*	P=0.095	P=0.175	P=0.092N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

---



TDMS No. 99017 - 06  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Diethylamine  
 CAS Number: 109-89-7

Date Report Requested: 10/23/2008  
 Time Report Requested: 13:20:12  
 First Dose M/F: 08/18/03 / 08/18/03  
 Lab: BNW

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Lung  
 Alveolar/Bronchiolar Adenoma**

**TUMOR RATES**

OVERALL (a)	2/50 (4%)	3/50 (6%)	2/50 (4%)	4/50 (8%)
POLY-3 RATE (b)	2/43.5	3/43.6	2/47.59	4/47.78
POLY-3 PERCENT (g)	4.6%	6.9%	4.2%	8.4%
TERMINAL (d)	2/32 (6%)	2/35 (6%)	2/36 (6%)	3/39 (8%)
FIRST INCIDENCE	731 (T)	649	731 (T)	610
HC TUMORS SAME RTE	15/300 (5%)			
HC TUMORS ALL RTES	61/1198 (5%)			

**STATISTICAL TESTS**

POLY 3	P=0.327	P=0.501	P=0.661N	P=0.382
POLY 1.5	P=0.312	P=0.503	P=0.672N	P=0.367
POLY 6	P=0.344	P=0.501	P=0.647N	P=0.398
COCH-ARM / FISHERS	P=0.281	P=0.500	P=0.691N	P=0.339
MAX-ISO-POLY-3	P=0.383	P=0.324	P=0.464N	P=0.246
HISTCONT SAME RTE	P=0.410	P=0.422	P=1.000	P=0.299
HISTCONT ALL RTES	P=0.444	P=0.408	P=1.000	P=0.302

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Lung  
Alveolar/Bronchiolar Carcinoma**

**TUMOR RATES**

OVERALL (a)	3/50 (6%)	1/50 (2%)	4/50 (8%)	1/50 (2%)
POLY-3 RATE (b)	3/43.64	1/43.75	4/47.59	1/47.37
POLY-3 PERCENT (g)	6.9%	2.3%	8.4%	2.1%
TERMINAL (d)	2/32 (6%)	0/35 (0%)	4/36 (11%)	1/39 (3%)
FIRST INCIDENCE	695	600	731 (T)	731 (T)
HC TUMORS SAME RTE	8/300 (3%)			
HC TUMORS ALL RTES	47/1198 (4%)			

**STATISTICAL TESTS**

POLY 3	P=0.299N	P=0.304N	P=0.547	P=0.277N
POLY 1.5	P=0.312N	P=0.303N	P=0.531	P=0.285N
POLY 6	P=0.286N	P=0.304N	P=0.565	P=0.268N
COCH-ARM / FISHERS	P=0.339N	P=0.309N	P=0.500	P=0.309N
MAX-ISO-POLY-3	P=0.254N	P=0.153N	P=0.395	P=0.144N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

---

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Lung  
Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma**

**TUMOR RATES**

OVERALL (a)	5/50 (10%)	4/50 (8%)	6/50 (12%)	5/50 (10%)
POLY-3 RATE (b)	5/43.64	4/44.05	6/47.59	5/47.78
POLY-3 PERCENT (g)	11.5%	9.1%	12.6%	10.5%
TERMINAL (d)	4/32 (13%)	2/35 (6%)	6/36 (17%)	4/39 (10%)
FIRST INCIDENCE	695	600	731 (T)	610
HC TUMORS SAME RTE	23/300 (8%)			
HC TUMORS ALL RTES	103/1198 (9%)			

**STATISTICAL TESTS**

POLY 3	P=0.557N	P=0.494N	P=0.560	P=0.572N
POLY 1.5	P=0.552	P=0.494N	P=0.540	P=0.590N
POLY 6	P=0.535N	P=0.492N	P=0.584	P=0.552N
COCH-ARM / FISHERS	P=0.503	P=0.500N	P=0.500	P=0.630N
MAX-ISO-POLY-3	P=0.658	P=0.357N	P=0.434	P=0.441N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

---

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>Mammary Gland Carcinoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	4/50 (8%)	1/50 (2%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	4/44.43	1/43.3	2/47.59	0/47.37
POLY-3 PERCENT (g)	9%	2.3%	4.2%	0%
TERMINAL (d)	1/32 (3%)	1/35 (3%)	2/36 (6%)	0/39 (0%)
FIRST INCIDENCE	584	731 (T)	731 (T)	---
HC TUMORS SAME RTE	3/300 (1%)			
HC TUMORS ALL RTES	15/1199 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.043N*	P=0.186N	P=0.306N	P=0.053N
POLY 1.5	P=0.045N*	P=0.181N	P=0.316N	P=0.055N
POLY 6	P=0.041N*	P=0.192N	P=0.296N	P=0.051N
COCH-ARM / FISHERS	P=0.051N	P=0.181N	P=0.339N	P=0.059N
MAX-ISO-POLY-3	P=0.021N*	P=0.091N	P=0.185N	P=0.019N*
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Mammary Gland  
Fibroma, Fibroadenoma, Carcinoma, or Adenoma**

TUMOR RATES	#	#	#	#
OVERALL (a)	5/50 (10%)	1/50 (2%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	5/45.17	1/43.3	2/47.59	0/47.37
POLY-3 PERCENT (g)	11.1%	2.3%	4.2%	0%
TERMINAL (d)	1/32 (3%)	1/35 (3%)	2/36 (6%)	0/39 (0%)
FIRST INCIDENCE	465	731 (T)	731 (T)	---
HC TUMORS SAME RTE	3/300 (1%)			
HC TUMORS ALL RTES	15/1199 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.020N*	P=0.111N	P=0.196N	P=0.027N*
POLY 1.5	P=0.021N*	P=0.106N	P=0.202N	P=0.028N*
POLY 6	P=0.019N*	P=0.117N	P=0.189N	P=0.026N*
COCH-ARM / FISHERS	P=0.025N*	P=0.102N	P=0.218N	P=0.028N*
MAX-ISO-POLY-3	P=0.007N**	P=0.053N	P=0.111N	P=0.010N**
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>Mesentery Hemangiosarcoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	2/43.5	0/43.3	0/47.59	1/47.37
POLY-3 PERCENT (g)	4.6%	0%	0%	2.1%
TERMINAL (d)	2/32 (6%)	0/35 (0%)	0/36 (0%)	1/39 (3%)
FIRST INCIDENCE	731 (T)	---	---	731 (T)
HC TUMORS SAME RTE	0/300 (0%)			
HC TUMORS ALL RTES	1/1199 (0%)			

**STATISTICAL TESTS**

POLY 3	P=0.457N	P=0.238N	P=0.218N	P=0.470N
POLY 1.5	P=0.459N	P=0.237N	P=0.224N	P=0.479N
POLY 6	P=0.455N	P=0.239N	P=0.210N	P=0.461N
COCH-ARM / FISHERS	P=0.461N	P=0.247N	P=0.247N	P=0.500N
MAX-ISO-POLY-3	P=0.130N	P=0.077N	P=0.076N	P=0.264N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>Ovary</b>				
<b>Cystadenoma</b>				
<b>TUMOR RATES</b>				
OVERALL (a)	3/49 (6%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	3/42.52	2/43.3	0/47.59	0/47.37
POLY-3 PERCENT (g)	7.1%	4.6%	0%	0%
TERMINAL (d)	3/32 (9%)	2/35 (6%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	731 (T)	731 (T)	---	---
HC TUMORS SAME RTE	17/291 (6%)			
HC TUMORS ALL RTES	46/1171 (4%)			

**STATISTICAL TESTS**

POLY 3	P=0.034N*	P=0.492N	P=0.100N	P=0.100N
POLY 1.5	P=0.035N*	P=0.489N	P=0.105N	P=0.105N
POLY 6	P=0.033N*	P=0.494N	P=0.094N	P=0.096N
COCH-ARM / FISHERS	P=0.039N*	P=0.490N	P=0.117N	P=0.117N
MAX-ISO-POLY-3	P=0.039N*	P=0.317N	P=0.037N*	P=0.037N*
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Pituitary Gland: Pars Distalis or Unspecified Site  
Adenoma**

**TUMOR RATES**

OVERALL (a)	10/50 (20%)	5/50 (10%)	6/50 (12%)	7/49 (14%)
POLY-3 RATE (b)	10/44.88	5/43.3	6/47.86	7/46.37
POLY-3 PERCENT (g)	22.3%	11.6%	12.5%	15.1%
TERMINAL (d)	7/32 (22%)	5/35 (14%)	4/36 (11%)	7/38 (18%)
FIRST INCIDENCE	465	731 (T)	680	731 (T)
HC TUMORS SAME RTE	41/294 (14%)			
HC TUMORS ALL RTES	96/1166 (8%)			

**STATISTICAL TESTS**

POLY 3	P=0.301N	P=0.144N	P=0.167N	P=0.270N
POLY 1.5	P=0.318N	P=0.136N	P=0.179N	P=0.281N
POLY 6	P=0.284N	P=0.153N	P=0.151N	P=0.260N
COCH-ARM / FISHERS	P=0.354N	P=0.131N	P=0.207N	P=0.314N
MAX-ISO-POLY-3	P=0.184N	P=0.093N	P=0.114N	P=0.195N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)



**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Pituitary Gland: Pars Distalis or Unspecified Site  
Carcinoma or Adenoma**

**TUMOR RATES**

OVERALL (a)	10/50 (20%)	6/50 (12%)	6/50 (12%)	7/49 (14%)
POLY-3 RATE (b)	10/44.88	6/43.3	6/47.86	7/46.37
POLY-3 PERCENT (g)	22.3%	13.9%	12.5%	15.1%
TERMINAL (d)	7/32 (22%)	6/35 (17%)	4/36 (11%)	7/38 (18%)
FIRST INCIDENCE	465	731 (T)	680	731 (T)
HC TUMORS SAME RTE	42/294 (14%)			
HC TUMORS ALL RTES	98/1166 (8%)			

**STATISTICAL TESTS**

POLY 3	P=0.269N	P=0.226N	P=0.167N	P=0.270N
POLY 1.5	P=0.285N	P=0.215N	P=0.179N	P=0.281N
POLY 6	P=0.253N	P=0.239N	P=0.151N	P=0.260N
COCH-ARM / FISHERS	P=0.320N	P=0.207N	P=0.207N	P=0.314N
MAX-ISO-POLY-3	P=0.222N	P=0.156N	P=0.114N	P=0.195N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Pituitary Gland: Pars Intermedia  
Adenoma**

**TUMOR RATES**

OVERALL (a)	2/50 (4%)	1/50 (2%)	0/50 (0%)	1/49 (2%)
POLY-3 RATE (b)	2/43.66	1/43.3	0/47.59	1/46.37
POLY-3 PERCENT (g)	4.6%	2.3%	0%	2.2%
TERMINAL (d)	1/32 (3%)	1/35 (3%)	0/36 (0%)	1/38 (3%)
FIRST INCIDENCE	690	731 (T)	---	731 (T)
HC TUMORS SAME RTE	3/294 (1%)			
HC TUMORS ALL RTES	12/1166 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.363N	P=0.503N	P=0.219N	P=0.479N
POLY 1.5	P=0.367N	P=0.500N	P=0.225N	P=0.487N
POLY 6	P=0.359N	P=0.506N	P=0.211N	P=0.471N
COCH-ARM / FISHERS	P=0.375N	P=0.500N	P=0.247N	P=0.508N
MAX-ISO-POLY-3	P=0.221N	P=0.283N	P=0.076N	P=0.270N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>Skeletal Muscle Hemangiosarcoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.5	0/43.3	0/47.59	0/47.37
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME RTE	0/300 (0%)			
HC TUMORS ALL RTES	1/1199 (0%)			

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Skin  
Fibroma, Fibrosarcoma, Sarcoma, Myxoma, Myxosarcoma, or Fibrous Histiocytoma**

TUMOR RATES	#	#	#	#
OVERALL (a)	4/50 (8%)	2/50 (4%)	6/50 (12%)	2/50 (4%)
POLY-3 RATE (b)	4/44.51	2/44.42	6/47.9	2/47.65
POLY-3 PERCENT (g)	9%	4.5%	12.5%	4.2%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	3/36 (8%)	1/39 (3%)
FIRST INCIDENCE	599	551	676	653
HC TUMORS SAME RTE	14/300 (5%)			
HC TUMORS ALL RTES	53/1199 (4%)			

**STATISTICAL TESTS**

POLY 3	P=0.337N	P=0.338N	P=0.417	P=0.306N
POLY 1.5	P=0.351N	P=0.335N	P=0.402	P=0.315N
POLY 6	P=0.323N	P=0.341N	P=0.434	P=0.299N
COCH-ARM / FISHERS	P=0.384N	P=0.339N	P=0.370	P=0.339N
MAX-ISO-POLY-3	P=0.325N	P=0.201N	P=0.300	P=0.185N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Skin  
Fibrosarcoma, Sarcoma, Myxosarcoma, or Fibrous Histiocytoma**

TUMOR RATES	#	#	#	#
OVERALL (a)	4/50 (8%)	2/50 (4%)	6/50 (12%)	2/50 (4%)
POLY-3 RATE (b)	4/44.51	2/44.42	6/47.9	2/47.65
POLY-3 PERCENT (g)	9%	4.5%	12.5%	4.2%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	3/36 (8%)	1/39 (3%)
FIRST INCIDENCE	599	551	676	653
HC TUMORS SAME RTE	14/300 (5%)			
HC TUMORS ALL RTES	53/1199 (4%)			

**STATISTICAL TESTS**

POLY 3	P=0.337N	P=0.338N	P=0.417	P=0.306N
POLY 1.5	P=0.351N	P=0.335N	P=0.402	P=0.315N
POLY 6	P=0.323N	P=0.341N	P=0.434	P=0.299N
COCH-ARM / FISHERS	P=0.384N	P=0.339N	P=0.370	P=0.339N
MAX-ISO-POLY-3	P=0.325N	P=0.201N	P=0.300	P=0.185N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>Skin</b>				
<b>Fibrous Histiocytoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	0/50 (0%)	1/50 (2%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.5	1/43.85	0/47.59	0/47.37
POLY-3 PERCENT (g)	0%	2.3%	0%	0%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	---	564	---	---
HC TUMORS SAME RTE	2/300 (1%)			
HC TUMORS ALL RTES	7/1199 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.567N	P=0.502	(e)	(e)
POLY 1.5	P=0.569N	P=0.502	(e)	(e)
POLY 6	P=0.564N	P=0.502	(e)	(e)
COCH-ARM / FISHERS	P=0.575N	P=0.500	(e)	(e)
MAX-ISO-POLY-3	P=0.389N	P=0.161	(e)	(e)
HISTCONT SAME RTE	(h)	(h)	(e)	(e)
HISTCONT ALL RTES	(h)	(h)	(e)	(e)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>Skin Sarcoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	4/50 (8%)	1/50 (2%)	6/50 (12%)	2/50 (4%)
POLY-3 RATE (b)	4/44.51	1/43.88	6/47.9	2/47.65
POLY-3 PERCENT (g)	9%	2.3%	12.5%	4.2%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	3/36 (8%)	1/39 (3%)
FIRST INCIDENCE	599	551	676	653
HC TUMORS SAME RTE	12/300 (4%)			
HC TUMORS ALL RTES	27/1199 (2%)			

**STATISTICAL TESTS**

POLY 3	P=0.384N	P=0.183N	P=0.417	P=0.306N
POLY 1.5	P=0.401N	P=0.179N	P=0.402	P=0.315N
POLY 6	P=0.368N	P=0.187N	P=0.434	P=0.299N
COCH-ARM / FISHERS	P=0.435N	P=0.181N	P=0.370	P=0.339N
MAX-ISO-POLY-3	P=0.310N	P=0.088N	P=0.300	P=0.185N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**Spleen  
Hemangiosarcoma**

**TUMOR RATES**

OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/43.5	0/43.3	0/47.59	0/47.37
POLY-3 PERCENT (g)	4.6%	0%	0%	0%
TERMINAL (d)	2/32 (6%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	731 (T)	---	---	---
HC TUMORS SAME RTE	3/297 (1%)			
HC TUMORS ALL RTES	24/1180 (2%)			

**STATISTICAL TESTS**

POLY 3	P=0.113N	P=0.238N	P=0.218N	P=0.219N
POLY 1.5	P=0.114N	P=0.237N	P=0.224N	P=0.224N
POLY 6	P=0.113N	P=0.239N	P=0.210N	P=0.213N
COCH-ARM / FISHERS	P=0.115N	P=0.247N	P=0.247N	P=0.247N
MAX-ISO-POLY-3	P=0.032N*	P=0.077N	P=0.076N	P=0.076N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

---



**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>Stomach, Forestomach Squamous Cell Carcinoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/43.5	0/43.3	0/47.59	0/47.37
POLY-3 PERCENT (g)	2.3%	0%	0%	0%
TERMINAL (d)	1/32 (3%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	731 (T)	---	---	---
HC TUMORS SAME RTE	1/300 (0%)			
HC TUMORS ALL RTES	2/1199 (0%)			

**STATISTICAL TESTS**

POLY 3	P=0.311N	P=0.501N	P=0.482N	P=0.483N
POLY 1.5	P=0.310N	P=0.500N	P=0.488N	P=0.488N
POLY 6	P=0.313N	P=0.502N	P=0.475N	P=0.477N
COCH-ARM / FISHERS	P=0.307N	P=0.500N	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.123N	P=0.160N	P=0.158N	P=0.158N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Stomach, Forestomach  
Squamous Cell Carcinoma or Papilloma Squamous**

TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	0/50 (0%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	1/43.5	0/43.3	1/47.59	1/47.37
POLY-3 PERCENT (g)	2.3%	0%	2.1%	2.1%
TERMINAL (d)	1/32 (3%)	0/35 (0%)	1/36 (3%)	1/39 (3%)
FIRST INCIDENCE	731 (T)	---	731 (T)	731 (T)
HC TUMORS SAME RTE	4/300 (1%)			
HC TUMORS ALL RTES	20/1199 (2%)			

**STATISTICAL TESTS**

POLY 3	P=0.572	P=0.501N	P=0.740N	P=0.741N
POLY 1.5	P=0.563	P=0.500N	P=0.747N	P=0.747N
POLY 6	P=0.583	P=0.502N	P=0.732N	P=0.735N
COCH-ARM / FISHERS	P=0.544	P=0.500N	P=0.753N	P=0.753N
MAX-ISO-POLY-3	P=0.577	P=0.160N	P=0.475N	P=0.476N
HISTCONT SAME RTE	P=0.543	(e)	P=0.424	P=0.422
HISTCONT ALL RTES	P=0.678	(e)	P=0.569	P=0.567

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Thyroid Gland: Follicular Cell Adenoma**

**TUMOR RATES**

OVERALL (a)	0/50 (0%)	1/50 (2%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/43.5	1/43.3	1/47.59	0/47.37
POLY-3 PERCENT (g)	0%	2.3%	2.1%	0%
TERMINAL (d)	0/32 (0%)	1/35 (3%)	1/36 (3%)	0/39 (0%)
FIRST INCIDENCE	---	731 (T)	731 (T)	---
HC TUMORS SAME RTE	8/299 (3%)			
HC TUMORS ALL RTES	28/1185 (2%)			

**STATISTICAL TESTS**

POLY 3	P=0.573N	P=0.499	P=0.518	(e)
POLY 1.5	P=0.580N	P=0.500	P=0.512	(e)
POLY 6	P=0.565N	P=0.498	P=0.525	(e)
COCH-ARM / FISHERS	P=0.597N	P=0.500	P=0.500	(e)
MAX-ISO-POLY-3	P=0.416N	P=0.158	P=0.180	(e)
HISTCONT SAME RTE	(h)	(h)	(h)	(e)
HISTCONT ALL RTES	(h)	(h)	(h)	(e)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>Tooth</b>				
<b>Odontoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.5	0/43.3	0/47.59	0/47.37
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME RTE	0/300 (0%)			
HC TUMORS ALL RTES	0/1199 (0%)			

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>Uterus</b>				
<b>Polyp Stromal</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	1/50 (2%)	2/50 (4%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	1/43.5	2/43.3	2/47.8	0/47.37
POLY-3 PERCENT (g)	2.3%	4.6%	4.2%	0%
TERMINAL (d)	1/32 (3%)	2/35 (6%)	1/36 (3%)	0/39 (0%)
FIRST INCIDENCE	731 (T)	731 (T)	676	---
HC TUMORS SAME RTE	14/300 (5%)			
HC TUMORS ALL RTES	33/1199 (3%)			

**STATISTICAL TESTS**

POLY 3	P=0.265N	P=0.498	P=0.533	P=0.483N
POLY 1.5	P=0.275N	P=0.501	P=0.521	P=0.488N
POLY 6	P=0.254N	P=0.496	P=0.547	P=0.477N
COCH-ARM / FISHERS	P=0.297N	P=0.500	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.243N	P=0.279	P=0.316	P=0.158N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>Uterus</b>				
<b>Sarcoma Stromal or Polyp Stromal</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	1/50 (2%)	3/50 (6%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	1/43.5	3/43.3	2/47.8	0/47.37
POLY-3 PERCENT (g)	2.3%	6.9%	4.2%	0%
TERMINAL (d)	1/32 (3%)	3/35 (9%)	1/36 (3%)	0/39 (0%)
FIRST INCIDENCE	731 (T)	731 (T)	676	---
HC TUMORS SAME RTE	16/300 (5%)			
HC TUMORS ALL RTES	39/1199 (3%)			

**STATISTICAL TESTS**

POLY 3	P=0.212N	P=0.303	P=0.533	P=0.483N
POLY 1.5	P=0.222N	P=0.306	P=0.521	P=0.488N
POLY 6	P=0.202N	P=0.301	P=0.547	P=0.477N
COCH-ARM / FISHERS	P=0.244N	P=0.309	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.191N	P=0.153	P=0.316	P=0.158N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>All Organs</b>				
<b>Hemangiosarcoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	5/50 (10%)	3/50 (6%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	5/43.95	3/43.6	0/47.59	2/47.37
POLY-3 PERCENT (g)	11.4%	6.9%	0%	4.2%
TERMINAL (d)	4/32 (13%)	2/35 (6%)	0/36 (0%)	2/39 (5%)
FIRST INCIDENCE	599	649	---	731 (T)
HC TUMORS SAME RTE	12/300 (4%)			
HC TUMORS ALL RTES	58/1199 (5%)			

**STATISTICAL TESTS**

POLY 3	P=0.102N	P=0.360N	P=0.024N*	P=0.187N
POLY 1.5	P=0.106N	P=0.356N	P=0.026N*	P=0.195N
POLY 6	P=0.098N	P=0.363N	P=0.022N*	P=0.178N
COCH-ARM / FISHERS	P=0.116N	P=0.357N	P=0.028N*	P=0.218N
MAX-ISO-POLY-3	P=0.045N*	P=0.235N	P=0.010N**	P=0.107N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>All Organs</b>				
<b>Histiocytic Sarcoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	1/43.52	0/43.3	0/47.59	1/47.62
POLY-3 PERCENT (g)	2.3%	0%	0%	2.1%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	726	---	---	662
HC TUMORS SAME RTE	8/300 (3%)			
HC TUMORS ALL RTES	31/1199 (3%)			

**STATISTICAL TESTS**

POLY 3	P=0.613	P=0.501N	P=0.482N	P=0.740N
POLY 1.5	P=0.607	P=0.500N	P=0.488N	P=0.747N
POLY 6	P=0.620	P=0.502N	P=0.475N	P=0.733N
COCH-ARM / FISHERS	P=0.597	P=0.500N	P=0.500N	P=0.753N
MAX-ISO-POLY-3	P=0.398N	P=0.160N	P=0.158N	P=0.475N
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)



**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

---

**All Organs**  
**Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed, NOS, or Undifferentiated Cell Type**

---

TUMOR RATES	#	#	#	#
OVERALL (a)	8/50 (16%)	15/50 (30%)	15/50 (30%)	13/50 (26%)
POLY-3 RATE (b)	8/46	15/44.5	15/48.21	13/47.65
POLY-3 PERCENT (g)	17.4%	33.7%	31.1%	27.3%
TERMINAL (d)	1/32 (3%)	12/35 (34%)	9/36 (25%)	11/39 (28%)
FIRST INCIDENCE	522	551	680	684
HC TUMORS SAME RTE	64/300 (21%)			
HC TUMORS ALL RTES	278/1199 (23%)			

**STATISTICAL TESTS**

---

POLY 3	P=0.278	P=0.059	P=0.094	P=0.184
POLY 1.5	P=0.268	P=0.067	P=0.089	P=0.182
POLY 6	P=0.284	P=0.051	P=0.100	P=0.183
COCH-ARM / FISHERS	P=0.229	P=0.077	P=0.077	P=0.163
MAX-ISO-POLY-3	P=0.121	P=0.038*	P=0.063	P=0.129
HISTCONT SAME RTE	P=0.145	P=0.042*	P=0.075	P=0.161
HISTCONT ALL RTES	P=0.139	P=0.040*	P=0.071	P=0.153

---

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>All Organs</b>				
<b>Benign Tumors</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	25/50 (50%)	28/50 (56%)	26/50 (52%)	26/50 (52%)
POLY-3 RATE (b)	25/45.49	28/45.61	26/48.41	26/48.4
POLY-3 PERCENT (g)	55%	61.4%	53.7%	53.7%
TERMINAL (d)	20/32 (63%)	22/35 (63%)	20/36 (56%)	22/39 (56%)
FIRST INCIDENCE	465	444	659	610
HC TUMORS SAME RTE	170/300 (57%)			
HC TUMORS ALL RTES	631/1199 (53%)			

**STATISTICAL TESTS**

POLY 3	P=0.394N	P=0.338	P=0.534N	P=0.535N
POLY 1.5	P=0.441N	P=0.350	P=0.574N	P=0.570N
POLY 6	P=0.343N	P=0.333	P=0.478N	P=0.495N
COCH-ARM / FISHERS	P=0.527	P=0.344	P=0.500	P=0.500
MAX-ISO-POLY-3	P=0.531N	P=0.263	P=0.451N	P=0.452N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99017 - 06  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Diethylamine  
 CAS Number: 109-89-7

Date Report Requested: 10/23/2008  
 Time Report Requested: 13:20:12  
 First Dose M/F: 08/18/03 / 08/18/03  
 Lab: BNW

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM
<b>All Organs</b>				
<b>Malignant Tumors</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	23/50 (46%)	28/50 (56%)	30/50 (60%)	27/50 (54%)
POLY-3 RATE (b)	23/47.03	28/47.65	30/48.67	27/49.21
POLY-3 PERCENT (g)	48.9%	58.8%	61.6%	54.9%
TERMINAL (d)	11/32 (34%)	19/35 (54%)	20/36 (56%)	19/39 (49%)
FIRST INCIDENCE	522	444	676	626
HC TUMORS SAME RTE	149/300 (50%)			
HC TUMORS ALL RTES	617/1199 (52%)			

**STATISTICAL TESTS**

POLY 3	P=0.381	P=0.223	P=0.146	P=0.352
POLY 1.5	P=0.357	P=0.228	P=0.140	P=0.335
POLY 6	P=0.406	P=0.216	P=0.155	P=0.368
COCH-ARM / FISHERS	P=0.283	P=0.212	P=0.115	P=0.274
MAX-ISO-POLY-3	P=0.288	P=0.168	P=0.107	P=0.284
HISTCONT SAME RTE	P=0.347	P=0.211	P=0.131	P=0.367
HISTCONT ALL RTES	P=0.335	P=0.202	P=0.124	P=0.354

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**All Organs  
Malignant and Benign Tumors**

TUMOR RATES	#	#	#	#
OVERALL (a)	41/50 (82%)	40/50 (80%)	41/50 (82%)	42/50 (84%)
POLY-3 RATE (b)	41/48.41	40/48.14	41/48.96	42/49.91
POLY-3 PERCENT (g)	84.7%	83.1%	83.7%	84.2%
TERMINAL (d)	26/32 (81%)	29/35 (83%)	29/36 (81%)	32/39 (82%)
FIRST INCIDENCE	465	444	659	610
HC TUMORS SAME RTE	240/300 (80%)			
HC TUMORS ALL RTES	916/1199 (76%)			

**STATISTICAL TESTS**

POLY 3	P=0.548N	P=0.526N	P=0.559N	P=0.581N
POLY 1.5	P=0.526	P=0.492N	P=0.552N	P=0.601N
POLY 6	P=0.509N	P=0.562N	P=0.558N	P=0.557N
COCH-ARM / FISHERS	P=0.403	P=0.500N	P=0.602N	P=0.500
MAX-ISO-POLY-3	P=0.682N	P=0.412N	P=0.447N	P=0.470N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**LEGEND**

- (a) Number of tumor-bearing animals/number of animals examined at site.
  - (b) Number of tumor-bearing animals/Poly-3 number
  - (d) Observed incidence at terminal kill.
  - (e) Value of Statistic cannot be computed.
  - (f) Beneath the control incidence are the P-values associated with the trend test. Beneath the dosed group incidence are the P-values corresponding to pairwise comparisons between the controls and that dosed group.
  - (g) Poly-3 adjusted lifetime tumor incidence.
  - (h) Value of Historical Controls statistic is only calculated when Poly-3 trend is positive and when there is more than one tumor in the treatment groups.
  - (I) Interim sacrifice
  - (T) Terminal sacrifice
  - # Tumor rates based on numbers of animals necropsied.
  - \* To the right of any statistical result, indicates significance at ( $P \leq 0.05$ ).
  - \*\* To the right of any statistical result, indicates significance at ( $P \leq 0.01$ ).
  - N Indicates a negative trend for all tests
- The Cochran-Armitage and Fishers exact tests compare directly the overall incidence rates.

\*\*\* END OF REPORT \*\*\*